barc201303016kbatch.htm
 
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549
 
 
FORM 6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
March 01, 2013
 
Barclays PLC and

Barclays Bank PLC
(Names of Registrants)
 
 
 1 Churchill Place

London E14 5HP
England
(Address of Principal Executive Offices)

 
 
 
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.

 
Form 20-F x           Form 40-F

 
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 
Yes           No x

 
If "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b):

 
This Report is a joint Report on Form 6-K filed by Barclays PLC and Barclays
Bank PLC. All of the issued ordinary share capital of Barclays Bank PLC is
owned by Barclays PLC.

 
This Report comprises:

 
Information given to The London Stock Exchange and furnished pursuant to
General Instruction B to the General Instructions to Form 6-K.


 
 
EXHIBIT INDEX
 
 




Exhibit No. 1   
  Director/PDMR Shareholding dated 08 February 2013
Exhibit No. 2  Total Voting Rights dated 14 February 2013
Exhibit No. 3     FRN Variable Rate Fix dated dated 19 February 2013
Exhibit No. 4  FRN Variable Rate Fix dated  dated 19 February 2013
Exhibit No. 5  Publication of Base Prospectus Supplement 19 February  2013
Exhibit No. 6  Publication of Base Prospectus Supplement 19 February 2013
Exhibit No. 7  FRN Variable Rate Fix dated 19 February 2013
Exhibit No. 8  Director/PDMR Shareholding 20 February 2013
Exhibit No. 9  Total Voting Rights 26 February 2013
Exhibit No. 10  FRN Variable Rate Fix dated 27 February 2013
Exhibit No. 11  Total Voting Rights 28 February 2013
 
 
 
 



SIGNATURES

 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, each of the registrants has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
 
 
BARCLAYS PLC
(Registrant)

 
Date: March 01, 2013
 
 
By: /s/ Patrick Gonsalves
----------------------
Patrick Gonsalves
Deputy Secretary
 
 
 
 
BARCLAYS BANK PLC
(Registrant)



Date: March 01, 2013
 
 
By: /s/ Patrick Gonsalves
----------------------
Patrick Gonsalves
Joint Secretary
 
 

 
Exhibit No. 1 
 

8 February 2013
 
 
 
Barclays PLC (the "Company")
 
 
Director/PDMR shareholding: Disclosure and Transparency Rules 3.1.4R (1) (a)
 
 
The trustee of the Barclays Group Sharepurchase Plan ("Sharepurchase"), an HM Revenue and Customs approved all employee share plan, informed the Company on 8 February 2013 that, on 7 February 2013 it had purchased, and now held as bare trustee of Sharepurchase, 42 ordinary shares in the Company at a price of £2.9664 per share, for Ashok Vaswani, a Person Discharging Managerial Responsibilities ("PDMR"). 
 
 
Exhibit No. 2
 

 
14 February 2013
 
 
Barclays PLC - Total Voting Rights and Capital
 
Reference is made to the announcement of 13 February 2013, which related to the exercise of 379,218,809 outstanding Barclays PLC warrants.
 
In conformity with the Disclosure and Transparency Rules, Barclays PLC's issued share capital consists of 12,623,369,281 ordinary shares with voting rights as at 14 February 2013.
 
There are no ordinary shares held in Treasury. 
 
The above figure (12,623,369,281) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Barclays PLC under the FSA's Disclosure and Transparency Rules. 
 
Exhibit No. 3
 
Re:
BARCLAYS BANK PLC.
 
GBP 2,000,000,000.00
 
MATURING: 16-May-2018
 
ISIN: XS0398795574
   
PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD
18-Feb-2013 TO 18-Mar-2013 HAS BEEN FIXED AT 1.042500 PCT
 
DAY BASIS: ACTUAL/365(FIX)
 
INTEREST PAYABLE VALUE 18-Mar-2013 WILL AMOUNT TO:
GBP 39.99 PER GBP 50,000.00 DENOMINATION
 
 
Barclays Bank PLC
 
 
Source: Barclays Bank PLC

Exhibit No. 4
 
Re:
BARCLAYS BANK PLC.
 
GBP 1,000,000,000.00
 
MATURING: 16-May-2019
 
ISIN: XS0398797604
   
PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD
18-Feb-2013 TO 18-Mar-2013 HAS BEEN FIXED AT 1.042500 PCT
 
DAY BASIS: ACTUAL/365(FIX)
 
INTEREST PAYABLE VALUE 18-Mar-2013 WILL AMOUNT TO:
GBP 39.99 PER GBP 50,000.00 DENOMINATION
 
 
Barclays Bank PLC
 
 
Source: Barclays Bank PLC
 
 
Exhibit No. 5
 

 
Publication of Base Prospectus Supplement
 
The following base prospectus supplement has been approved by the UK Listing Authority and is available for viewing:
 
Base Prospectus Supplement No. 3 dated 19 February 2013 to the Base Prospectus dated 1 June 2012 for the Barclays PLC and Barclays Bank PLC £60,000,000,000 Debt Issuance Programme
 
To view the full document, please paste the following URL into the address bar of your browser
 
http://www.rns-pdf.londonstockexchange.com/rns/2300Y_1-2013-2-19.pdf
 
A copy of the above document has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do
 
For further information, please contact:
 
Barclays Treasury
1 Churchill Place
Canary Wharf
London E14 5HP
 
DISCLAIMER - INTENDED ADDRESSEES
 
IMPORTANT: You must read the following before continuing: The following disclaimer applies to the Base Prospectus Supplement available by clicking on the link above, and you are therefore advised to read this disclaimer carefully before reading, accessing or making any other use of the Base Prospectus Supplement. In accessing the Base Prospectus Supplement, you agree to be bound by the following terms and conditions, including any modifications to them, any time you receive any information from us as a result of such access.
 
THE BASE PROSPECTUS SUPPLEMENT MAY NOT BE FORWARDED OR DISTRIBUTED OTHER THAN AS PROVIDED BELOW AND MAY NOT BE REPRODUCED IN ANY MANNER WHATSOEVER. THE BASE PROSPECTUS SUPPLEMENT MAY ONLY BE DISTRIBUTED OUTSIDE THE UNITED STATES TO PERSONS THAT ARE NOT U.S. PERSONS AS DEFINED IN, AND IN RELIANCE ON, REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR WITHIN THE UNITED STATES TO QIBs (AS DEFINED BELOW) IN ACCORDANCE WITH RULE 144A UNDER THE SECURITIES ACT ("RULE 144A"). ANY FORWARDING, DISTRIBUTION OR REPRODUCTION OF THE BASE PROSPECTUS SUPPLEMENT IN WHOLE OR IN PART IS PROHIBITED. FAILURE TO COMPLY WITH THIS NOTICE MAY RESULT IN A VIOLATION OF THE SECURITIES ACT OR THE APPLICABLE LAWS OF OTHER JURISDICTIONS.
 
NOTHING IN THIS ELECTRONIC PUBLICATION CONSTITUTES AN OFFER OF SECURITIES FOR SALE IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO DO SO. ANY NOTES ISSUED OR TO BE ISSUED PURSUANT TO THE BASE PROSPECTUS RELATING TO THE BARCLAYS PLC AND BARCLAYS BANK PLC £60,000,000,000 DEBT ISSUANCE PROGRAMME (THE "BASE PROSPECTUS") AND THE BASE PROSPECTUS SUPPLEMENT HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES ACT OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES.
 
ANY NOTES ISSUED OR TO BE ISSUED PURSUANT TO THE BASE PROSPECTUS AND THE BASE PROSPECTUS SUPPLEMENT MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT (1) IN ACCORDANCE WITH RULE 144A UNDER THE SECURITIES ACT TO PERSONS REASONABLY BELIEVED TO BE QUALIFIED INSTITUTIONAL BUYERS (EACH A "QIB") WITHIN THE MEANING OF RULE 144A OR (2) IN AN OFFSHORE TRANSACTION TO A PERSON THAT IS NOT A U.S. PERSON IN ACCORDANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE SECURITIES ACT.
 
Please note that the information contained in the Base Prospectus Supplement may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Prospectus is not addressed. Prior to relying on the information contained in the Base Prospectus and the Base Prospectus Supplement you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of the information contained therein.
 
Confirmation of your Representation: In order to be eligible to view the Base Prospectus Supplement or make an investment decision with respect to any Notes issued or to be issued pursuant to the Base Prospectus and the Base Prospectus Supplement, you must be (i) a person other than a U.S. person (within the meaning of Regulation S under the Securities Act); or (ii) a QIB that is acquiring the securities for its own account or for the account of another QIB. By accessing the Base Prospectus Supplement, you shall be deemed to have represented that (i) you and any customers you represent are (a) QIBs or (b) not a U.S. person (as defined in Regulation S to the Securities Act) located outside the U.S.; and (ii) you consent to delivery of the Base Prospectus Supplement and any amendments or supplements thereto via electronic transmission.
 
You are reminded that the Base Prospectus Supplement has been made available to you on the basis that you are a person into whose possession the Base Prospectus Supplement may be lawfully delivered in accordance with the laws of the jurisdiction in which you are located and you may not, nor are you authorised to, deliver the Base Prospectus Supplement, electronically or otherwise, to any other person.
 
The Base Prospectus Supplement does not constitute, and may not be used in connection with, an offer or solicitation in any place where offers or solicitations are not permitted by law. If a jurisdiction requires that the offering be made by a licensed broker or dealer and the underwriters or any affiliate of the underwriters is a licensed broker or dealer in that jurisdiction, the offering shall be deemed to be made by the underwriters or such affiliate on behalf of the issuers in such jurisdiction. Under no circumstances shall the Base Prospectus Supplement constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of any Notes issued or to be issued pursuant to the Base Prospectus and the Base Prospectus Supplement, in any jurisdiction in which such offer, solicitation or sale would be unlawful.
 
The Base Prospectus Supplement has been made available to you in an electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission and consequently none of the issuers, their advisers nor any person who controls any of them nor any director, officer, employee nor agent of it or affiliate of any such person accepts any liability or responsibility whatsoever in respect of any difference between the Base Prospectus Supplement made available to you in electronic format and the hard copy version available to you on request from the issuers.
 

Exhibit No. 6
 

 
Publication of Base Prospectus Supplement
 
The following base prospectus supplement has been approved by the UK Listing Authority and is available for viewing:
 
Base Prospectus Supplement No. 3 dated 19 February 2013 to the Base Prospectus dated 1 June 2012 for the Barclays PLC and Barclays Bank PLC £60,000,000,000 Debt Issuance Programme
 
To view the full document, please paste the following URL into the address bar of your browser
 
http://www.rns-pdf.londonstockexchange.com/rns/2304Y_1-2013-2-19.pdf
 
A copy of the above document has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do
 
For further information, please contact:
 
Barclays Treasury
1 Churchill Place
Canary Wharf
London E14 5HP
 
DISCLAIMER - INTENDED ADDRESSEES
 
IMPORTANT: You must read the following before continuing: The following disclaimer applies to the Base Prospectus Supplement available by clicking on the link above, and you are therefore advised to read this disclaimer carefully before reading, accessing or making any other use of the Base Prospectus Supplement. In accessing the Base Prospectus Supplement, you agree to be bound by the following terms and conditions, including any modifications to them, any time you receive any information from us as a result of such access.
 
THE BASE PROSPECTUS SUPPLEMENT MAY NOT BE FORWARDED OR DISTRIBUTED OTHER THAN AS PROVIDED BELOW AND MAY NOT BE REPRODUCED IN ANY MANNER WHATSOEVER. THE BASE PROSPECTUS SUPPLEMENT MAY ONLY BE DISTRIBUTED OUTSIDE THE UNITED STATES TO PERSONS THAT ARE NOT U.S. PERSONS AS DEFINED IN, AND IN RELIANCE ON, REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR WITHIN THE UNITED STATES TO QIBs (AS DEFINED BELOW) IN ACCORDANCE WITH RULE 144A UNDER THE SECURITIES ACT ("RULE 144A"). ANY FORWARDING, DISTRIBUTION OR REPRODUCTION OF THE BASE PROSPECTUS SUPPLEMENT IN WHOLE OR IN PART IS PROHIBITED. FAILURE TO COMPLY WITH THIS NOTICE MAY RESULT IN A VIOLATION OF THE SECURITIES ACT OR THE APPLICABLE LAWS OF OTHER JURISDICTIONS.
 
NOTHING IN THIS ELECTRONIC PUBLICATION CONSTITUTES AN OFFER OF SECURITIES FOR SALE IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO DO SO. ANY NOTES ISSUED OR TO BE ISSUED PURSUANT TO THE BASE PROSPECTUS RELATING TO THE BARCLAYS PLC AND BARCLAYS BANK PLC £60,000,000,000 DEBT ISSUANCE PROGRAMME (THE "BASE PROSPECTUS") AND THE BASE PROSPECTUS SUPPLEMENT HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES ACT OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES.
 
ANY NOTES ISSUED OR TO BE ISSUED PURSUANT TO THE BASE PROSPECTUS AND THE BASE PROSPECTUS SUPPLEMENT MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT (1) IN ACCORDANCE WITH RULE 144A UNDER THE SECURITIES ACT TO PERSONS REASONABLY BELIEVED TO BE QUALIFIED INSTITUTIONAL BUYERS (EACH A "QIB") WITHIN THE MEANING OF RULE 144A OR (2) IN AN OFFSHORE TRANSACTION TO A PERSON THAT IS NOT A U.S. PERSON IN ACCORDANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE SECURITIES ACT.
 
Please note that the information contained in the Base Prospectus Supplement may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Prospectus is not addressed. Prior to relying on the information contained in the Base Prospectus and the Base Prospectus Supplement you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of the information contained therein.
 
Confirmation of your Representation: In order to be eligible to view the Base Prospectus Supplement or make an investment decision with respect to any Notes issued or to be issued pursuant to the Base Prospectus and the Base Prospectus Supplement, you must be (i) a person other than a U.S. person (within the meaning of Regulation S under the Securities Act); or (ii) a QIB that is acquiring the securities for its own account or for the account of another QIB. By accessing the Base Prospectus Supplement, you shall be deemed to have represented that (i) you and any customers you represent are (a) QIBs or (b) not a U.S. person (as defined in Regulation S to the Securities Act) located outside the U.S.; and (ii) you consent to delivery of the Base Prospectus Supplement and any amendments or supplements thereto via electronic transmission.
 
You are reminded that the Base Prospectus Supplement has been made available to you on the basis that you are a person into whose possession the Base Prospectus Supplement may be lawfully delivered in accordance with the laws of the jurisdiction in which you are located and you may not, nor are you authorised to, deliver the Base Prospectus Supplement, electronically or otherwise, to any other person.
 
The Base Prospectus Supplement does not constitute, and may not be used in connection with, an offer or solicitation in any place where offers or solicitations are not permitted by law. If a jurisdiction requires that the offering be made by a licensed broker or dealer and the underwriters or any affiliate of the underwriters is a licensed broker or dealer in that jurisdiction, the offering shall be deemed to be made by the underwriters or such affiliate on behalf of the issuers in such jurisdiction. Under no circumstances shall the Base Prospectus Supplement constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of any Notes issued or to be issued pursuant to the Base Prospectus and the Base Prospectus Supplement, in any jurisdiction in which such offer, solicitation or sale would be unlawful.
 
The Base Prospectus Supplement has been made available to you in an electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission and consequently none of the issuers, their advisers nor any person who controls any of them nor any director, officer, employee nor agent of it or affiliate of any such person accepts any liability or responsibility whatsoever in respect of any difference between the Base Prospectus Supplement made available to you in electronic format and the hard copy version available to you on request from the issuers.
 

Exhibit No. 7
 
As Agent Bank, please be advised of the following rate determined on: 15/02/2013
Issue
¦ Barclays Bank Plc - Series 53 EUR 50,000,000 FRN due 19 Feb 2029
   
ISIN Number
¦ XS0093415288
ISIN Reference
¦ 9341528
Issue Nomin EUR
¦ 50000000
Period
¦ 19/02/2013 to 19/02/2014
  
Payment Date 19/02/2014
Number of Days
¦ -200000
Rate
¦ 2.163
  
Denomination EUR
¦ 10000
  
¦ 50000000
  
¦
     
Amount Payable per Denomination
¦ 216.3
  
¦ 1081500. 0
  
¦
     
Bank of New York
    
Rate Fix Desk
Telephone
  
¦ 44 1202 689580
Corporate Trust Services
Facsimile
  
¦ 44 1202 689601
 
 
Barclays Bank PLC
 
 
Source: Barclays Bank PLC
 
 
Exhibit No. 8
 

 

 
 
20 February 2013 
Barclays PLC
("the Company")
 
Director/PDMR shareholding: Disclosure and Transparency Rules 3.1.4R (1) (a)
 
On 19 February 2013 the following ordinary shares in Barclays PLC ("the Company") were purchased on the London Stock Exchange on behalf of the Chairman and the non-executive Directors of the Company at a price of £3.24009 per share.  These purchases arise from the policy of using part of fee payable to each such Director to purchase shares in the Company, which, together with any reinvested dividends, are retained for the Director until they leave the Board.
 
 
DIRECTOR
 
BARCLAYS PLC SHARES PURCHASED
TOTAL BENEFICIAL INTEREST FOLLOWING THIS NOTIFICATION
 
TOTAL NON-BENEFICIAL INTEREST FOLLOWING THIS NOTIFICATION
David Booth
2,489
94,550
-
Tim Breedon
655
2,655
-
Fulvio Conti
2,963
60,978
-
Simon Fraser
2,667
90,637
-
Reuben Jeffery¹
3,680
128,148
-
Sir Andrew Likierman
2,515
42,835
-
Dambisa Moyo
2,666
19,232
-
Sir Michael Rake
2,386
45,211
-
Sir John Sunderland
2,487
98,302
-
Sir David Walker
4,601
81,904
-
 
 
¹ Reuben Jeffery's beneficial interest comprises 25,000 American Depositary Shares and 28,148 Ordinary Shares in Barclays PLC
 
Exhibit No. 9
 
 

26 February 2013
 
 
 
Barclays PLC - Total Voting Rights and Capital
 
In conformity with the Disclosure and Transparency Rules, following the allotment of 237,000,000 shares under the Barclays Share Value Plan on 25 February 2013, Barclays PLC's issued share capital consists of 12,860,575,306 ordinary shares with voting rights as at 26 February 2013.
 
There are no ordinary shares held in Treasury. 
 
The above figure (12,860,575,306) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Barclays PLC under the FSA's Disclosure and Transparency Rules. 
 
 
 
Exhibit No. 10
 
As Agent Bank, please be advised of the following rate determined on: 27/02/2013
Issue
¦ Barclays Bank PLC - Series 112 EUR 50,000,000 Subordinated FRN due 01 Mar 2022
   
ISIN Number
¦ XS0144176996
ISIN Reference
¦ 14417699
Issue Nomin EUR
¦ 50000000
Period
¦ 01/03/2013 to 02/09/2013
  
Payment Date 02/09/2013
Number of Days
¦ 185
Rate
¦ 0.736
  
Denomination EUR
¦ 100000
  
¦ 50000000
  
¦
     
Amount Payable per Denomination
¦ 378.22
  
¦ 189111.11
  
¦
     
Bank of New York
    
Rate Fix Desk
Telephone
  
¦ 44 1202 689580
Corporate Trust Services
Facsimile
  
¦ 44 1202 689601
 
27/02/2013 frn
 
 
Barclays Bank PLC
 
 
Source: Barclays Bank PLC
 
 

Exhibit No. 11
 

 
 
 
28 February 2013
 
 
 
Barclays PLC - Total Voting Rights and Capital
 
In conformity with the Disclosure and Transparency Rules, Barclays PLC's issued share capital consists of 12,860,662,729 ordinary shares with voting rights as at 28 February 2013.
 
There are no ordinary shares held in Treasury. 
 
The above figure (12,860,662,729) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Barclays PLC under the FSA's Disclosure and Transparency Rules.